Shattuck Labs Provides Corporate Update and Highlights Upcoming Key Milestones in 2023
09 janv. 2023 07h00 HE
|
Shattuck Labs, Inc.
AUSTIN, TX & DURHAM, NC, Jan. 09, 2023 (GLOBE NEWSWIRE) -- Shattuck Labs, Inc. (Shattuck) (NASDAQ: STTK), a clinical-stage biotechnology company pioneering the development of bi-functional...
Mettler-Toledo International Inc. Announces Webcast of Presentation at the 41st Annual J.P. Morgan Healthcare Conference
20 déc. 2022 16h15 HE
|
Mettler-Toledo, LLC
Columbus, OH, Dec. 20, 2022 (GLOBE NEWSWIRE) -- Mettler-Toledo International Inc. (NYSE:MTD) today announced the webcast of its presentation at the 41st Annual JP Morgan Healthcare Conference on...
Tome Puts AI to Work With First-Ever Generative Storytelling Tool
20 déc. 2022 09h00 HE
|
Tome
SAN FRANCISCO, Dec. 20, 2022 (GLOBE NEWSWIRE) -- Tome, the AI-powered storytelling format for work and important ideas, today introduced generative storytelling. Launching in beta, Tome’s AI enables...
Mettler-Toledo International Inc. Announces Webcast of Presentation at the Virtual 5th Annual Evercore ISI HealthCONx Conference
16 nov. 2022 16h15 HE
|
Mettler-Toledo, LLC
Columbus, OH, Nov. 16, 2022 (GLOBE NEWSWIRE) -- Mettler-Toledo International Inc. (NYSE:MTD) today announced the webcast of its presentation at the virtual 5th Annual Evercore ISI HealthCONx...
Shattuck Labs Reports Third Quarter 2022 Financial Results and Recent Business Highlights
08 nov. 2022 16h30 HE
|
Shattuck Labs, Inc.
– Completed enrollment in Phase 1 dose-escalation clinical trial of SL-172154 as monotherapy in platinum-resistant ovarian cancer; complete data expected midyear 2023 – – Dosed first patient in...
Compass Therapeutics to Present at Upcoming Investment Conferences
08 nov. 2022 08h00 HE
|
Compass Therapeutics
BOSTON, Nov. 08, 2022 (GLOBE NEWSWIRE) -- Compass Therapeutics, Inc. (Nasdaq: CMPX), a clinical-stage biopharmaceutical company developing proprietary antibody-based therapeutics to treat cancer,...
Shattuck Labs Presents Updated Preclinical Data on Gamma Delta T Cell Engager (GADLEN) Platform Candidates at the Society for Immunotherapy of Cancer (SITC) Annual Meeting
07 nov. 2022 08h00 HE
|
Shattuck Labs, Inc.
- Data from two distinct GADLEN product candidates, one targeting CD20 and another targeting B7-H3, enhanced γδT cell killing of tumor cells, demonstrating preclinical proof-of-concept in the...
Shattuck Labs Announces Participation in Upcoming November Conferences
03 nov. 2022 08h30 HE
|
Shattuck Labs, Inc.
AUSTIN, TX and DURHAM, NC, Nov. 03, 2022 (GLOBE NEWSWIRE) -- Shattuck Labs, Inc. (Shattuck) (NASDAQ: STTK), a clinical-stage biotechnology company pioneering the development of bi-functional fusion...
Shattuck Labs to Report Third Quarter 2022 Financial Results on November 8, 2022
01 nov. 2022 16h30 HE
|
Shattuck Labs, Inc.
AUSTIN, TX and DURHAM, NC, Nov. 01, 2022 (GLOBE NEWSWIRE) -- Shattuck Labs, Inc. (Shattuck) (NASDAQ: STTK), a clinical-stage biotechnology company pioneering the development of bi-functional fusion...
Mettler-Toledo International Inc. to Webcast Investor Meeting
28 oct. 2022 16h15 HE
|
Mettler-Toledo, LLC
Columbus, OH, Oct. 28, 2022 (GLOBE NEWSWIRE) -- Mettler-Toledo International Inc. (NYSE:MTD) today announced it will host an investor meeting in the Boston area on November 7, 2022. A live webcast...